SRT2104 attenuated lipopolysaccharide-induced release of the cytokines interleukin-6 ( mean peak levels of 58.8 % [ p < 0.05 ] and 80.9 % [ p = 0.078 ] after single and repeated SRT2104 administration , respectively , relative to those measured after placebo treatment ) and interleukin-8 ( mean peak levels of 57.0 % [ p < 0.05 vs placebo ] and 77.1 % [ p < 0.05 vs placebo ] after single and repeated SRT2104 ingestion , respectively , while not affecting tumor necrosis factor - and interleukin-10 release ) .